Please use this identifier to cite or link to this item: https://doi.org/10.1186/1476-4598-11-14
Title: Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma
Authors: Poh, W.
Wong, W.
Ong, H.
Aung, M.O.
Lim, S.G.
Chua, B.T.
Ho, H.K. 
Keywords: FGFR4
Hepatocellular carcinoma
KLB
Liver stemness
Issue Date: 23-Mar-2012
Source: Poh, W., Wong, W., Ong, H., Aung, M.O., Lim, S.G., Chua, B.T., Ho, H.K. (2012-03-23). Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Molecular Cancer 11 : -. ScholarBank@NUS Repository. https://doi.org/10.1186/1476-4598-11-14
Abstract: Background: We had previously demonstrated overexpression of fibroblast growth factor receptor-4 (FGFR4) in hepatocellular carcinoma (HCC). However, additional molecular mechanisms resulting in amplified FGFR4 signaling in HCC remain under-studied. Here, we studied the mechanistic role of its co-receptor klotho-beta (KLB) in driving elevated FGFR4 activity in HCC progression.Results: Quantitative real-time PCR analysis identified frequent elevation of KLB gene expression in HCC tumors relative to matched non-tumor tissue, with a more than two-fold increase correlating with development of multiple tumors in patients. KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling. While transient repression of KLB-FGFR4 signaling decreased protein expression of alpha-fetoprotein (AFP), a HCC diagnostic marker, prolonged inhibition enriched for resistant HCC cells exhibiting increased liver stemness.Conclusions: Elevated KLB expression in HCC tissues provides further credence to the oncogenic role of increased FGFR4 signaling in HCC progression and represents a novel biomarker to identify additional patients amenable to anti-FGFR4 therapy. The restricted tissue expression profile of KLB, together with the anti-proliferative effect observed with KLB-silencing, also qualifies it as a specific and potent therapeutic target for HCC patients. The enrichment of a liver stem cell-like population in response to extended KLB-FGFR4 repression necessitates further investigation to target the development of drug resistance. © 2012 Poh et al; licensee BioMed Central Ltd.
Source Title: Molecular Cancer
URI: http://scholarbank.nus.edu.sg/handle/10635/106103
ISSN: 14764598
DOI: 10.1186/1476-4598-11-14
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2012-klotho_beta_overexpression_novel_target-published.pdf1.03 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

20
checked on Jan 16, 2018

WEB OF SCIENCETM
Citations

20
checked on Nov 22, 2017

Page view(s)

32
checked on Jan 13, 2018

Download(s)

4
checked on Jan 13, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.